South Korea
· Delayed Price · Currency is KRW EyeGene Statistics
Total Valuation
EyeGene has a market cap or net worth of KRW 87.31 billion. The enterprise value is 54.35 billion.
| Market Cap | 87.31B |
| Enterprise Value | 54.35B |
Important Dates
The next estimated earnings date is Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
EyeGene has 27.03 million shares outstanding. The number of shares has increased by 13.69% in one year.
| Shares Outstanding | 27.03M |
| Shares Change (YoY) | +13.69% |
| Shares Change (QoQ) | -0.88% |
| Owned by Insiders (%) | 6.59% |
| Owned by Institutions (%) | 0.13% |
| Float | 19.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 27.77 |
| PB Ratio | 1.56 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.41 |
| EV / Sales | 19.13 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.99 |
Financial Position
The company has a current ratio of 7.33, with a Debt / Equity ratio of 6.70.
| Current Ratio | 7.33 |
| Quick Ratio | 7.13 |
| Debt / Equity | 6.70 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.21 |
| Interest Coverage | -30.46 |
Financial Efficiency
Return on equity (ROE) is -24.45% and return on invested capital (ROIC) is -19.07%.
| Return on Equity (ROE) | -24.45% |
| Return on Assets (ROA) | -16.40% |
| Return on Capital (ROIC) | -19.07% |
| Revenue Per Employee | 60.44M |
| Profits Per Employee | -262.45M |
| Employee Count | 47 |
| Asset Turnover | 0.04 |
| Inventory Turnover | 4.00 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -15.36% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -15.36% |
| 50-Day Moving Average | 3,312.10 |
| 200-Day Moving Average | 3,235.55 |
| Relative Strength Index (RSI) | 42.57 |
| Average Volume (20 Days) | 428,372 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, EyeGene had revenue of KRW 2.84 billion and -12.34 billion in losses. Loss per share was -504.97.
| Revenue | 2.84B |
| Gross Profit | 1.71B |
| Operating Income | -18.02B |
| Pretax Income | -13.71B |
| Net Income | -12.34B |
| EBITDA | -15.51B |
| EBIT | -18.02B |
| Loss Per Share | -504.97 |
Balance Sheet
The company has 37.26 billion in cash and 3.79 billion in debt, giving a net cash position of 33.47 billion or 1,238.40 per share.
| Cash & Cash Equivalents | 37.26B |
| Total Debt | 3.79B |
| Net Cash | 33.47B |
| Net Cash Per Share | 1,238.40 |
| Equity (Book Value) | 56.49B |
| Book Value Per Share | 2,070.80 |
| Working Capital | 33.62B |
Cash Flow
In the last 12 months, operating cash flow was -17.24 billion and capital expenditures -931.54 million, giving a free cash flow of -18.17 billion.
| Operating Cash Flow | -17.24B |
| Capital Expenditures | -931.54M |
| Free Cash Flow | -18.17B |
| FCF Per Share | -672.37 |
Margins
| Gross Margin | 60.20% |
| Operating Margin | -634.26% |
| Pretax Margin | -482.62% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -639.76% |
Dividends & Yields
EyeGene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.69% |
| Shareholder Yield | -13.69% |
| Earnings Yield | -15.63% |
| FCF Yield | -20.82% |
Stock Splits
The last stock split was on June 28, 2021. It was a forward split with a ratio of 1.2.
| Last Split Date | Jun 28, 2021 |
| Split Type | Forward |
| Split Ratio | 1.2 |